277 related articles for article (PubMed ID: 24504055)
41. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
[TBL] [Abstract][Full Text] [Related]
42. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
43. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
44.
Rodrigues RS; Bozza FA; Hanrahan CJ; Wang LM; Wu Q; Hoffman JM; Zimmerman GA; Morton KA
Nucl Med Biol; 2017 May; 48():52-62. PubMed ID: 28237630
[TBL] [Abstract][Full Text] [Related]
45. Fluorine-18-deoxyglucose positron emission tomography/computed tomography with Ki67 and GLUT-1 immunohistochemistry for evaluation of the radiosensitization effect of oleanolic acid on C6 rat gliomas.
Zhang Y; Xu H; Wang H; Yu W; Zhao X; Xue Y
Nucl Med Commun; 2015 Jan; 36(1):21-7. PubMed ID: 25222909
[TBL] [Abstract][Full Text] [Related]
46. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
[TBL] [Abstract][Full Text] [Related]
47. Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: A Multitracer Positron Emission Tomography Imaging Study in Mice.
Wuest M; Hamann I; Bouvet V; Glubrecht D; Marshall A; Trayner B; Soueidan OM; Krys D; Wagner M; Cheeseman C; West F; Wuest F
Mol Pharmacol; 2018 Feb; 93(2):79-89. PubMed ID: 29142019
[TBL] [Abstract][Full Text] [Related]
48.
Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y
Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983
[TBL] [Abstract][Full Text] [Related]
49. Clinical correlations with (18)FDG PET scan patterns in solid pseudopapillary tumors of the pancreas: still a surgical enigma?
Kang CM; Cho A; Kim H; Chung YE; Hwang HK; Choi SH; Lee WJ
Pancreatology; 2014; 14(6):515-23. PubMed ID: 25256437
[TBL] [Abstract][Full Text] [Related]
50. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
[TBL] [Abstract][Full Text] [Related]
51. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
52. What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro.
Ogawa M; Nakamura S; Saito Y; Kosugi M; Magata Y
J Nucl Med; 2012 Jan; 53(1):55-8. PubMed ID: 22128324
[TBL] [Abstract][Full Text] [Related]
53. Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.
Smith TA; Appleyard MV; Sharp S; Fleming IN; Murray K; Thompson AM
Cancer Chemother Pharmacol; 2013 Feb; 71(2):473-80. PubMed ID: 23178956
[TBL] [Abstract][Full Text] [Related]
54. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas.
Yamada T; Uchida M; Kwang-Lee K; Kitamura N; Yoshimura T; Sasabe E; Yamamoto T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):464-71. PubMed ID: 22676927
[TBL] [Abstract][Full Text] [Related]
55. Correlation between ¹⁸F-FDG uptake and the expression of glucose transporter-1 and hypoxia-inducible factor-1α in transplanted VX2 tumors.
Xu H; Li B; Yu W; Wang H; Zhao X; Yao Y; Huang D
Nucl Med Commun; 2013 Oct; 34(10):953-8. PubMed ID: 23887273
[TBL] [Abstract][Full Text] [Related]
56. Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma.
Hatano T; Zhao S; Zhao Y; Nishijima K; Kuno N; Hanzawa H; Sakamoto T; Tamaki N; Kuge Y
Int J Oncol; 2013 Mar; 42(3):823-30. PubMed ID: 23338175
[TBL] [Abstract][Full Text] [Related]
57. Noninvasive
Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
[TBL] [Abstract][Full Text] [Related]
58. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer.
Lyshchik A; Higashi T; Hara T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T; Togashi K
Cancer Invest; 2007; 25(3):154-62. PubMed ID: 17530485
[TBL] [Abstract][Full Text] [Related]
59. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Sharma RI; Smith TA
J Nucl Med; 2008 Aug; 49(8):1386-94. PubMed ID: 18632807
[TBL] [Abstract][Full Text] [Related]
60. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
Kim SL; Kim EM; Cheong SJ; Lee CM; Kim DW; Jeong HJ; Lim ST; Sohn MH; Yim CY
Nucl Med Biol; 2009 May; 36(4):427-33. PubMed ID: 19423011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
